Targeting Mitochondria by Olesoxime or Complement 1q Binding Protein as a Novel Management for Autism: A Hypothesis

A. Ghanizadeh

Research Center for Psychiatry and Behavioral Sciences, Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran

Key Words
Autism · Complement · Mitochondria · Permeability transition pore · Treatment

Abstract
Excitotoxicity, oxidative stress, and mitochondrial dysfunction are associated with autism. Considering the preventive role of complement 1q binding protein or olesoxime for the opening of mitochondrial permeability transition pore mediated by oxidative stress, it is hypothesized that complement 1q binding protein or olesoxime may improve some symptoms of autism.

The disturbance of antioxidant mechanisms and/or overproduction of free radicals may result in oxidative stress. It is largely recognized that oxidative stress is enhanced in autism [Mostafa et al., 2010; Palmieri and Persico, 2010]. For example, nitric oxide (NO) production is enhanced [Sweeten et al., 2004]. In addition, the activity of antioxidant systems such as superoxide dismutase enzyme [Meguid et al., 2010] and glutathione reserve capacity is lower in autism than in control groups [James et al., 2009]. In fact, there is a vicious cycle that the impairment of mitochondrial function causes a greater extent of oxidative stress [Palmieri and Persico, 2010].

NO induces oxidative stress and mitochondria are a target for NO (fig. 1). Toxicity with NO slows down the respiratory chain [Clementi et al., 1998] leading to cellular ATP depletion [Brorson et al., 1999]. The inhibition of respiration contributes to disruption of the mitochondrial inner transmembrane potential [Hortelano et al., 1997] leading to the activation of mitochondrial permeability transition pore (mPTP) and NO-induced apoptosis [Hortelano et al., 1997]. Furthermore, it is suggested that antioxidant supplements plus polyunsaturated fatty acids improve autism [Meguid et al., 2010]. Moreover, mitochondrial energy metabolism is impaired and ATP levels are decreased in autism [Pastural et al., 2009; Palmieri and Persico, 2010]. Autism in itself is not a homogeneous disorder but a symptom occurring in many disorders with variable causes. Only in a small percentage of patients a mitochondrial abnormality has been reported [Palmieri and Persico, 2010]. Moreover, equilibrium in reactive oxygen species in physiological conditions is required. At present, there is not any curative approach for autism. Furthermore, there are just a few Food and Drug Administration-approved medications that are available...
for treatment of autism. Therefore, there is an urgent need to find new solutions for autism treatment.

On the other hand, glutamate neurotoxicity [Harada et al., 2010] and excitotoxicity inflammation [Chauhan and Chauhan, 2006] are reported in autism. Moreover, glutamate synthesis inhibition decreases the neurotoxic activity in autism [Maezawa and Jin, 2010]. Meanwhile, the activation of the NMDA receptor may increase the NO level [Horn et al., 2002]. Cell death due to NMDA receptor agonists is reduced by blockade of NO synthesis [Kollegger et al., 1993]. Neuroinflammation, excitotoxicity, and oxidative stress are suggested as possible targets for treatment of autism [Ghanizadeh, 2010a, b, 2011a–c].

The mPTP is probably involved in neuronal injury due to excitotoxicity [Schinder et al., 1996]. Moreover, NO causes the release of calcium from mitochondria and induces intracellular calcium release by mPTP opening [Horn et al., 2002]. This leads to excitotoxicity.

Olesoxime is from the family of cholesterol-oximes that binds to some specific outer mitochondrial membrane proteins and prevents permeability transition pore opening mediated by oxidative stress [Bordet et al., 2010]. The neuroprotective effect of olesoxime is based on targeting mitochondria. The orally active compound of olesoxime is tolerated well. Complement 1q binding protein also prevents the mPTP opening through binding to cyclophilin D [McGee and Baines, 2010]. These phenomena will protect cells against oxidative stress.

In conclusion, the production of NO is increased [Sweeten et al., 2004] and oxidative stress is enhanced in autism [Mostafa et al., 2010; Palmieri and Persico, 2010]. Moreover, NO increases mPTP opening [Horn et al., 2002] and mitochondrial functioning is impaired in autism [Palmieri and Persico, 2010]. In addition, complement 1q binding protein [McGee and Baines, 2010] and olesoxime prevent permeability transition pore opening mediated by oxidative stress [Bordet et al., 2010]. Therefore, it is hypothesized that complement 1q binding protein or olesoxime may improve the condition of some patients with autism. So, it is worthwhile conducting the translational appropriate animal model studies to assess mitochondrial functioning [Patterson, 2011] that may open up novel possibilities for autism management.


Schinder AF, Olson EC, Spitzer NC, Montal M: Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16:6125–6133 (1996).